Physician profile
Vishal Jivan
NPI 1154563278
$4,904.01
in general payments reported to CMS, 2019-2025
21 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $559 · 2021: $138 · 2022: $523 · 2023: $904 · 2024: $554 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,710.28 | 2019-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $1,490.98 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Ethicon INC. | $566.44 | 2019-2025 | Monarch Platform |
| Steris Corporation | $197.60 | 2024 | |
| Genzyme Corporation | $138.92 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $125.70 | 2019 | |
| Atricure, INC. | $90.02 | 2023 | |
| Mylan Specialty L.P. | $62.00 | 2019-2023 | Yupelri |
| Philips North America LLC | $61.24 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $59.93 | 2022-2023 | Dupixent |
| Genentech USA, INC. | $56.50 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.26 | 2019-2020 | |
| Amgen INC. | $53.21 | 2023 | Tezspire |
| Astellas Pharma US INC | $43.56 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.85 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $38.87 | 2022 | |
| Portola Pharmaceuticals, LLC | $26.21 | 2019-2020 | |
| Medtronic, INC. | $23.27 | 2025 | Bis |
| Takeda Pharmaceuticals U.S.A., INC. | $21.93 | 2024 | Glassia |
| Grifols USA, LLC | $20.06 | 2019 | |
| Ethicon US, LLC | $18.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Jivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.